- MeiraGTx strikes royalty deal; Fore's 2023 Series D continuesPlus, news about Kalohexis, Teva and Agios: 👑 MeiraGTx makes royalty deal with Oberland Capital: The gene therapy maker will get an initial $135 million via a $10 million equity investment ...Endpoints · 20d ago↗ source
- Conquering Medicare's ACCESS programThere was so much excitement when CMS announced the ACCESS program. Finally, a way for digital health companies to make their mark on Medicare! A program that pays only if patients get better! Bu…Endpoints · 21d ago↗ source
- Vertex to acquire Crinetics in $10B foray into endocrine disease drugs<p>Vertex claimed the two drugs in the deal could eventually bring in more than $5 billion annually. Still, the high price it paid stirred debate among analysts and investors.</p>BioPharma Dive